Beigene (ONC) News Today $262.41 -1.01 (-0.38%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock Why is Beigene Down Today?Beigene, Ltd. (NASDAQ:ONC) shares have moved in response to a mix of insider activity and upcoming corporate events. BeOne Medicines will host an Investor R&D Day webcast on June 26, 2025, in New York City to give an in-depth update on its global oncology pipeline and new assets. Reported short interest remains at zero shares as of June 10, indicating limited current bearish positioning. CEO John Oyler sold 5,127 shares on June 6 at an average price of $252.77, totaling roughly $1.30 million. COO Xiaobin Wu sold 1,934 shares on the same day at an average of $253.15, for about $489,600. Insider Lai Wang disposed of 1,402 shares at $252.39 each (approx. $353,850). SVP Chan Henry Lee sold 700 shares at $256.11, totaling $179,277. Competitor Glenmark Pharma secured approval to launch its blood cancer treatment Brukinsa in India, potentially intensifying market competition. The cluster of senior‐executive stock sales has pressured ONC shares, while the R&D Day event offers a catalyst for potential upside depending on pipeline news.Posted 36m agoAI Generated. May Contain Errors. ONC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved IndicationsJune 11 at 4:05 PM | businesswire.comBeigene, Ltd. (NASDAQ:ONC) SVP Sells $179,277.00 in StockJune 11 at 6:49 AM | insidertrades.comBeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025June 11 at 6:01 AM | businesswire.comBeigene (NASDAQ:ONC) Shares Down 0.1% on Insider SellingBeigene (NASDAQ:ONC) Trading Down 0.1% on Insider SellingJune 11 at 12:16 AM | marketbeat.comInsider Selling: Beigene, Ltd. (NASDAQ:ONC) SVP Sells 700 Shares of StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 700 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $256.11, for a total transaction of $179,277.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.June 10 at 5:50 PM | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Lai Wang Sells 1,402 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,402 shares of Beigene stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $252.39, for a total transaction of $353,850.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.June 10 at 5:49 PM | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 1,934 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 1,934 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $253.15, for a total transaction of $489,592.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.June 10 at 5:47 PM | marketbeat.comJohn Oyler Sells 5,127 Shares of Beigene, Ltd. (NASDAQ:ONC) StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 5,127 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.June 10 at 5:43 PM | marketbeat.comCancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To TripleJune 5, 2025 | investors.comBeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025June 2, 2025 | businesswire.comBeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025May 31, 2025 | businesswire.comBeOne Launches Following Move to SwitzerlandMay 27, 2025 | baystreet.caBeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human UseMay 27, 2025 | marketwatch.comBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal CancerMay 27, 2025 | finance.yahoo.comBeiGene gets EU backing for neck and head cancer treatmentMay 27, 2025 | msn.comBeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global OncologyMay 27, 2025 | businesswire.comBeigene (NASDAQ:ONC) Rating Increased to Buy at StockNews.comStockNews.com upgraded Beigene from a "hold" rating to a "buy" rating in a research report on Thursday.May 24, 2025 | marketbeat.comBeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid TumorsMay 22, 2025 | finance.yahoo.comBeigene, Ltd. (NASDAQ:ONC) Receives Average Rating of "Buy" from BrokeragesShares of Beigene, Ltd. (NASDAQ:ONC - Get Free Report) have been given an average recommendation of "Buy" by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among analysts thatMay 21, 2025 | marketbeat.comBeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer StudiesMay 16, 2025 | finance.yahoo.comBeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation InnovationMay 14, 2025 | businesswire.comBeigene (NASDAQ:ONC) Shares Gap Down - Time to Sell?Beigene (NASDAQ:ONC) Shares Gap Down - Should You Sell?May 14, 2025 | marketbeat.comEarnings Preview: BeiGeneMay 13, 2025 | benzinga.comBeiGene to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2025 | uk.finance.yahoo.comBeiGene to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2025 | businesswire.comLeerink Partnrs Estimates Beigene's Q2 Earnings (NASDAQ:ONC)Beigene, Ltd. (NASDAQ:ONC - Free Report) - Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for shares of Beigene in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the company wilMay 13, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Releases Quarterly Earnings Results, Beats Estimates By $1.93 EPSBeigene (NASDAQ:ONC - Get Free Report) announced its earnings results on Wednesday. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.May 11, 2025 | marketbeat.comEarnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 10, 2025 | finance.yahoo.comLei Zhang and Hillhouse Capital: Quiet Power in Asian InvestingMay 9, 2025 | uk.finance.yahoo.comBeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...May 9, 2025 | uk.finance.yahoo.comBeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside PotentialMay 9, 2025 | msn.comBeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New ProfitMay 8, 2025 | seekingalpha.comBeiGene-Aktien fallen um über 5% - Q1-Umsatz die Erwartungen verfehltMay 8, 2025 | de.investing.comChinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings BeatMay 7, 2025 | benzinga.comBeiGene Q1 2025 Earnings PreviewMay 6, 2025 | msn.comLeerink Partnrs Estimates Beigene's Q1 Earnings (NASDAQ:ONC)Beigene, Ltd. (NASDAQ:ONC - Free Report) - Research analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Beigene in a note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.61) foMay 3, 2025 | marketbeat.comFY2026 EPS Estimates for Beigene Cut by Leerink PartnrsBeigene, Ltd. (NASDAQ:ONC - Free Report) - Research analysts at Leerink Partnrs reduced their FY2026 earnings estimates for Beigene in a report issued on Monday, April 28th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of $6.73 per share for the year, down froMay 2, 2025 | marketbeat.comBeiGene gewinnt US-Patentstreit über KrebsmedikamentMay 1, 2025 | de.investing.comUS-amerikanisches Patent- und Markenamt erklärt das gegen BeiGene geltend gemachte Pharmacyclics-Patent für ungültigMay 1, 2025 | de.finance.yahoo.comBeigene's (ONC) "Outperform" Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and set a $312.00 target price on shares of Beigene in a research report on Monday.April 30, 2025 | marketbeat.comU.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGeneApril 29, 2025 | businesswire.com3 Stocks That Could Be Trading Below Their Estimated Fair ValueApril 29, 2025 | uk.finance.yahoo.comBeiGene (ONC) Receives a Buy from TD CowenApril 25, 2025 | markets.businessinsider.comBeigene (NASDAQ:ONC) Shares Gap Up Following Analyst UpgradeBeigene (NASDAQ:ONC) Shares Gap Up After Analyst UpgradeApril 24, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Given New $317.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday.April 23, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $10,133,481.60 in StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 41,760 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $242.66, for a total transaction of $10,133,481.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.April 18, 2025 | marketbeat.comBeigene's (ONC) Buy Rating Reaffirmed at GuggenheimGuggenheim reiterated a "buy" rating on shares of Beigene in a report on Wednesday.April 18, 2025 | marketbeat.comBeiGene to Announce First Quarter 2025 Financial Results on May 7April 17, 2025 | businesswire.comBeiGene Up Over 10%, on Pace for Largest Percent Increase Since February 2024 — Data TalkApril 13, 2025 | morningstar.comAI-focused drug discovery firms rise as FDA phases out animal testingApril 11, 2025 | msn.com Get Beigene News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Media Mentions By Week ONC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONC News Sentiment▼-0.141.01▲Average Medical News Sentiment ONC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONC Articles This Week▼146▲ONC Articles Average Week Get Beigene News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News TAK News ARGX News BNTX News TEVA News SMMT News GMAB News ITCI News RDY News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONC) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beigene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
